Abstract Number: 067 • 2026 Pediatric Rheumatology Symposium
Standardizing Effective Education and Intervention for Chronic Non-Inflammatory Pain in Children with Juvenile Idiopathic Arthritis: A Quality Improvement Initiative
Background/Purpose: 5-10% of patients with juvenile idiopathic arthritis (JIA) can have chronic pain lasting >3 months despite well-controlled disease. This pain is from altered pain-related sensory pathways in the periphery and central…Abstract Number: 075 • 2026 Pediatric Rheumatology Symposium
Association of Anti-Cytokine Biologics and JAK inhibitors with Bronchoalveolar Fluid Cytokine Profiles in Patients with Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD)
Background/Purpose: Lung disease associated with systemic JIA (SJIA-LD) remains poorly understood. Compared to serum or plasma, measurement of cytokine levels in bronchoalveolar lavage fluid (BALF)…Abstract Number: 018 • 2026 Pediatric Rheumatology Symposium
Abnormal Cortical Grey Matter, White Matter and Subcortical Grey Matter Morphometry is Associated with Disease Features and Quality of Life in Patients with Craniofacial Localized Scleroderma
Background/Purpose: Craniofacial localized scleroderma (Cf-LS) is a rare autoimmune disorder that affects face and scalp tissues and is often diagnosed during childhood. Children with Cf-LS…Abstract Number: 055 • 2026 Pediatric Rheumatology Symposium
Referrals Leading to Rheumatologic Diagnosis in a Pediatric Rheumatology Center: Influence of Referring Provider Practice and Training
Background/Purpose: Recently, there has been a dramatic increase in referrals made to pediatric rheumatologists (PR) for non-specific symptoms and test results rather than overt signs…Abstract Number: 047 • 2026 Pediatric Rheumatology Symposium
Association of anti-DFS70 with autoimmune diseases in children
Background/Purpose: The ANA 23 panel is widely requested in patients with positive ANA to guide their association with autoimmune diseases; however, the anti-DFS70 antibody has…Abstract Number: 068 • 2026 Pediatric Rheumatology Symposium
Identification of Challenges in the Quality of Referrals to a Pediatric Rheumatology Center: A Retrospective Chart Review
Background/Purpose: Recently, there has been an increase in referrals to Pediatric Rheumatology (PR) for non-specific symptoms and test results rather than clearcut inflammatory and/or autoimmune…Abstract Number: 045 • 2026 Pediatric Rheumatology Symposium
Genotypes and Clinical Phenotypes of Monogenic Autoinflammatory Disorders in Michigan
Background/Purpose: Data regarding monogenic systemic autoinflammatory disorders (SAID) from the USA is scarce. Our study aims to report the spectrum of SAID and detail unique…Abstract Number: 066 • 2026 Pediatric Rheumatology Symposium
Incidence of Juvenile Idiopathic Arthritis in Chile: Estimates from a National Universal Access Program, 2010-2024
Background/Purpose: The incidence of juvenile idiopathic arthritis (JIA) varies widely among countries, and currently, updated data for Latin America and Chile are not available. The…Abstract Number: 072 • 2026 Pediatric Rheumatology Symposium
SOCS1 Haploinsufficiency: Functional Evidence Supporting an Expanded Clinical Phenotype
Background/Purpose: Insufficiency of Suppressor of Cytokine Signaling 1 (SOCS1) typically manifests with autoimmune features. Recently, some cases have also shown autoinflammatory traits such as recurrent…Abstract Number: 034 • 2026 Pediatric Rheumatology Symposium
Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Management Across Countries: A Survey to Inform Future Comparative Effectiveness Research
Background/Purpose: Background: PFAPA is the most common autoinflammatory condition of childhood. Its frequency, clinical features, and response to treatments vary across populations. To standardize care, the…Abstract Number: 029 • 2026 Pediatric Rheumatology Symposium
Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis
Background/Purpose: Methotrexate (MTX) is effective and steroid-sparing for pediatric non-infectious anterior uveitis, but whether subcutaneous (SC) achieves control faster than oral (PO) remains unclear. High-dose…Abstract Number: 053 • 2026 Pediatric Rheumatology Symposium
Association between Childhood Opportunity Index and Disparities in Health Care Access and Utilization in Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: Disparities in pediatric health outcomes are well described. The role of social determinants of health (SDOH) in the persistence of such disparities is increasingly…Abstract Number: 074 • 2026 Pediatric Rheumatology Symposium
Tissue Protein Expression Profiling of Interferon Gamma and Frizzled-Wnt-related Signaling Show Increased Periadnexal and Perivascular Localization in Juvenile Localized Scleroderma Skin
Background/Purpose: Localized scleroderma (LS) is a disease of inflammatory fibrosis affecting skin and deeper tissue, but the mechanisms driving fibrosis are poorly understood. Although fibroblasts…Abstract Number: 057 • 2026 Pediatric Rheumatology Symposium
Pediatric Learners’ Knowledge Retention and Diagnostic Confidence after High-Fidelity Pediatric Rheumatology Simulation
Background/Purpose: High-fidelity simulation is an effective tool in pediatric medical education. At our institution, residents spend two or fewer weeks rotating through pediatric rheumatology. The ACGME’s core competencies for pediatric…Abstract Number: 064 • 2026 Pediatric Rheumatology Symposium
Recognizing Paradoxical Psoriasis in TNF-Inhibitor–Treated Pediatric Rheumatic Disease: A Saskatchewan Experience
Background/Purpose: Paradoxical psoriasis is an increasingly recognized adverse effect of biologic therapy in pediatric rheumatology, most often with TNF-α inhibitors (TNF-i) such as adalimumab and…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 2616
- Next Page »